Jason B Muhitch
Overview
Explore the profile of Jason B Muhitch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
503
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hughson A, Hannon G, Salama N, Vrooman T, Stockwell C, Mills B, et al.
Mol Ther Nucleic Acids
. 2024 Oct;
35(4):102350.
PMID: 39469666
Pronounced T cell exhaustion characterizes immunosuppressive tumors, with the tumor microenvironment (TME) employing multiple mechanisms to elicit this suppression. Traditional immunotherapies, such as immune checkpoint blockade, often fail due to...
2.
Salgia N, Aubrecht W, Wang L, Ram B, Wasik B, Khan A, et al.
Eur Urol Oncol
. 2024 Mar;
7(5):973-977.
PMID: 38480032
Sarcomatoid renal cell carcinoma (sRCC) is histologically heterogeneous, with variable sarcomatoid amounts intermixed within epithelial carcinoma. However, the current classification for this aggressive disease is homogeneous and agnostic to the...
3.
Alvarez-Arzola R, Oliver L, Messmer M, Twum D, Lee K, Muhitch J, et al.
J Immunol
. 2023 Dec;
212(3):475-486.
PMID: 38117752
Macrophages represent the most abundant immune component of the tumor microenvironment and often exhibit protumorigenic (M2-like) phenotypes that contribute to disease progression. Despite their generally accepted protumorigenic role, macrophages can...
4.
Hughson A, Hannon G, Salama N, Vrooman T, Stockwell C, Mills B, et al.
bioRxiv
. 2023 Nov;
PMID: 37961513
Statement Of Significance: This study demonstrates the use of a novel combination treatment consisting of radiation and immunotherapy in murine pancreatic tumors. This treatment could effectively treat local and metastatic...
5.
Chow J, Khan A, Gaudieri M, Wasik B, Conway A, Soh K, et al.
J Immunother Cancer
. 2023 Apr;
11(4).
PMID: 37080610
Background: Studies evaluating peripheral patient samples show radiation can modulate immune responses, yet the biological changes in human tumors particularly at the cellular level remain largely unknown. Here, we address...
6.
Oliver L, Alvarez R, Diaz R, Valdes A, Colligan S, Nemeth M, et al.
J Immunother Cancer
. 2022 Sep;
10(9).
PMID: 36150744
Background: Immune suppression is common in neoplasia and a major driver is tumor-induced myeloid dysfunction. Yet, overcoming such myeloid cell defects remains an untapped strategy to reverse suppression and improve...
7.
Greene C, Attwood K, Sharma N, Balderman B, Deng R, Muhitch J, et al.
Front Oncol
. 2022 Aug;
12:923043.
PMID: 35992801
Iron is a potent catalyst of oxidative stress and cellular proliferation implicated in renal cell carcinoma (RCC) tumorigenesis, yet it also drives ferroptosis that suppresses cancer progression and represents a...
8.
Fountzilas C, Bajor D, Mukherjee S, Saltzman J, Witkiewicz A, Maguire O, et al.
Clin Cancer Res
. 2021 Oct;
27(24):6726-6736.
PMID: 34645646
Purpose: We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with wild-type (RASwt), metastatic colorectal adenocarcinoma (mCRC). Patients And Methods: In this phase Ib/II study, cetuximab...
9.
Chow J, Hoffend N, Abrams S, Schwaab T, Singh A, Muhitch J
Proc Natl Acad Sci U S A
. 2020 Sep;
117(38):23721-23729.
PMID: 32900949
Clinical studies combining radiation and immunotherapy have shown promising response rates, strengthening efforts to sensitize tumors to immune-mediated attack. Thus, there is an ongoing surge in trials using preconditioning regimens...
10.
Ito F, Vardam T, Appenheimer M, Eng K, Gollnick S, Muhitch J, et al.
Int J Hyperthermia
. 2019 Dec;
36(sup1):22-36.
PMID: 31795828
The aim of this study is to investigate whether radiofrequency ablation (RFA) improves the efficacy of adoptive T cell immunotherapy in preclinical mouse cancer models. Mice implanted subcutaneously () with...